These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 34307367)

  • 1. Combination Foretinib and Anti-PD-1 Antibody Immunotherapy for Colorectal Carcinoma.
    Fu Y; Peng Y; Zhao S; Mou J; Zeng L; Jiang X; Yang C; Huang C; Li Y; Lu Y; Wu M; Yang Y; Kong T; Lai Q; Wu Y; Yao Y; Wang Y; Gou L; Yang J
    Front Cell Dev Biol; 2021; 9():689727. PubMed ID: 34307367
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering TGF-β inhibitor-encapsulated macrophage-inspired multi-functional nanoparticles for combination cancer immunotherapy.
    Kim J; Kim M; Yong SB; Han H; Kang S; Lahiji SF; Kim S; Hong J; Seo Y; Kim YH
    Biomater Res; 2023 Dec; 27(1):136. PubMed ID: 38111068
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The VIPR2-selective antagonist KS-133 changes macrophage polarization and exerts potent anti-tumor effects as a single agent and in combination with an anti-PD-1 antibody.
    Sakamoto K; Kittikulsuth W; Miyako E; Steeve A; Ishimura R; Nakagawa S; Ago Y; Nishiyama A
    PLoS One; 2023; 18(7):e0286651. PubMed ID: 37405999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting acid ceramidase enhances antitumor immune response in colorectal cancer.
    Vijayan Y; James S; Viswanathan A; Aparna JS; Bindu A; Namitha NN; Anantharaman D; Babu Lankadasari M; Harikumar KB
    J Adv Res; 2023 Dec; ():. PubMed ID: 38142035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low dose novel PARP-PI3K inhibition via nanoformulation improves colorectal cancer immunoradiotherapy.
    Landry MR; DuRoss AN; Neufeld MJ; Hahn L; Sahay G; Luxenhofer R; Sun C
    Mater Today Bio; 2020 Sep; 8():100082. PubMed ID: 33294836
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subclone from CT26 resistant to anti-PD-1 therapy associated with increased expression of genes related to glucocorticoids.
    Zhang Y; Zhang C; Chen G; You H; Wang S; Wang X; Zhao P; Xu B; Gao Q; Yuan L
    Transl Oncol; 2024 Aug; 46():102031. PubMed ID: 38861853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neutralization of the adaptor protein PAG by monoclonal antibody limits murine tumor growth.
    Strazza M; Moore EK; Adam K; Azoulay-Alfaguter I; Mor A
    Mol Ther Methods Clin Dev; 2022 Dec; 27():380-390. PubMed ID: 36419471
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Author Correction: Modulation of tumor immune microenvironment by TAS-115, a multi-receptor tyrosine kinase inhibitor, promotes antitumor immunity and contributes anti-PD-1 antibody therapy.
    Shibutani T; Goto R; Miyazaki I; Hashimoto A; Suzuki T; Ishida K; Haruma T; Osada T; Harada T; Fujita H; Ohkubo S
    Sci Rep; 2024 Feb; 14(1):4784. PubMed ID: 38413675
    [No Abstract]   [Full Text] [Related]  

  • 9. Differential Immune-Related Microenvironment Determines Programmed Cell Death Protein-1/Programmed Death-Ligand 1 Blockade Efficacy in Patients With Advanced NSCLC.
    Shirasawa M; Yoshida T; Shimoda Y; Takayanagi D; Shiraishi K; Kubo T; Mitani S; Matsumoto Y; Masuda K; Shinno Y; Okuma Y; Goto Y; Horinouchi H; Ichikawa H; Kohno T; Yamamoto N; Matsumoto S; Goto K; Watanabe SI; Ohe Y; Motoi N
    J Thorac Oncol; 2021 Dec; 16(12):2078-2090. PubMed ID: 34419685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
    Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
    JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improving the efficacy of immunotherapy for colorectal cancer: Targeting tumor microenvironment-associated immunosuppressive cells.
    Zou D; Xin X; Xu Y; Xu H; Huang L; Xu T
    Heliyon; 2024 Aug; 10(16):e36446. PubMed ID: 39262952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis.
    Zou C; Shen J; Xu F; Ye Y; Wu Y; Xu S
    J Cancer; 2024; 15(11):3510-3530. PubMed ID: 38817865
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyclonal antibodies selectively inhibit tumor growth and invasion and synergize with immune checkpoint inhibitors.
    Ciron C; Morice P; Rousse J; Roy P; Royer PJ; Gauthier O; Brouard S; Duvaux O; Bassissi F; Vanhove B
    JCI Insight; 2024 Feb; 9(3):. PubMed ID: 38085594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanobiological Strategies to Augment Cancer Treatment.
    Kumari A; Veena SM; Luha R; Tijore A
    ACS Omega; 2023 Nov; 8(45):42072-42085. PubMed ID: 38024751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy.
    Liu S; Wang H; Shao X; Chen H; Chao S; Zhang Y; Gao Z; Yao Q; Zhang P
    J Nanobiotechnology; 2023 Jul; 21(1):207. PubMed ID: 37403095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DKK3 expression is associated with immunosuppression and poor prognosis in glioblastoma, in contrast to lower-grade gliomas.
    Han MH; Baek JM; Min KW; Cheong JH; Ryu JI; Won YD; Kwon MJ; Koh SH
    BMC Neurol; 2023 May; 23(1):183. PubMed ID: 37149563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of tumor-associated macrophages in common digestive system malignant tumors.
    Shen Y; Chen JX; Li M; Xiang Z; Wu J; Wang YJ
    World J Gastrointest Oncol; 2023 Apr; 15(4):596-616. PubMed ID: 37123058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Receptor tyrosine kinase inhibitors in cancer.
    Ebrahimi N; Fardi E; Ghaderi H; Palizdar S; Khorram R; Vafadar R; Ghanaatian M; Rezaei-Tazangi F; Baziyar P; Ahmadi A; Hamblin MR; Aref AR
    Cell Mol Life Sci; 2023 Mar; 80(4):104. PubMed ID: 36947256
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted mechanical forces enhance the effects of tumor immunotherapy by regulating immune cells in the tumor microenvironment.
    Zhu P; Lu H; Wang M; Chen K; Chen Z; Yang L
    Cancer Biol Med; 2023 Jan; 20(1):44-55. PubMed ID: 36647779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Novel IGF-1R Inhibitor PB-020 Acts Synergistically with Anti-PD-1 and Mebendazole against Colorectal Cancer.
    Kang B; Zhang X; Wang W; She S; Chen W; Chen C; Wang Y; Pan X; Xu O; Wang Y
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.